The next year, the authors reported that the scAAV9 vector carrying the SMN gene (scAAV9-SMN) was injected into the facial vein of neonatal SMA model mice on the first day after birth, resulting in prolonged survival of one of the treated mice [111]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.